“It brings me joy to make sure that I can get families through the tough periods. Knowing that I’ve made a difference.”
Dr Robert Lim
Dr Robert Lim is a graduate of both the University of St Andrews and University of Edinburgh where he obtained his medical degree (MBChB). He then moved to New York where he completed his postgraduate training in Internal Medicine followed by Haematology and Medical Oncology at The New York Hospital – Cornell University Medical College and Memorial Sloan Kettering Cancer Center. In addition to his American Board certifications in Internal Medicine, Medical Oncology and Haematology, Dr Lim is also a Fellow of the Royal College of Physicians in Edinburgh. After returning to Singapore in 1998, he has developed special clinical interest in gastrointestinal, liver and pancreatic cancers.
Besides his skills in clinical care, he has co-authored several pivotal major studies in colon cancer and pancreatic cancer that have influenced clinical practice. From 2005 to 2011, he was the Head of the Department of Haematology-Oncology at the National University Cancer Institute, Singapore (NCIS). In particular, the focus in developing new drug treatments and enhancing the understanding of the unique problem for Asians with cancer has helped many patients and their families.
He has been a member of the Specialist Training Committee in Medical Oncology, instrumental in training many doctors both in internal medicine and oncology, providing invaluable mentorship and guidance. Amongst his many varied responsibilities, he has served as an Associate Director of NCIS and is a previous council member of Dover Park Hospice, chairing their medical professional audit committee.
Affiliations & Memberships
- Member of American Society of Clinical Oncology
- Member of European Society of Medical Oncology
- Colon cancer
- Gastrointestinal cancer
- Liver cancer
Phase II APEC trial: The impact of primary tumor side on outcomes of first‐line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild‐type metastatic colorectal cancer. Timothy Price, Lin Shen, Brigette Ma, Regina Esser, Wenfeng Chen, Peter Gibbs, Robert Lim, Ann‐Lii Cheng. Asia-Pacific Journal of Clinical Oncology 2019; 15: 225 -230.
Efficacy, tolerability, and biomarker analyses of once-every-2-weeks cetuximab plus first-line FOLFOX or FOLFIRI in patients with KRAS or all RAS wild-type metastatic colorectal cancer: the phase 2 APEC study. A.L. Cheng, Kensei Yamaguchi, M.D.; Gerardo Cornelio; Lin Shen; Timothy Price; Tsai-Sheng Yang; Ik Joo Chung; Guang-Hai Dai; Jen-Kou Lin; Atul Sharma; Kun-Huei Yeh; Brigette Ma; Adel Zaatar; Zhongzhen Guan; Nehal Masood; Vichien Srimuninnimit; Thomas Yau; Peter Gibbs; Xiuwen Wang; Dinesh Chandra Doval; Seung-Taek Oh; Byoung Yong Shim; Charity Gorospe; Hwei-Ming Wang; Ekaphop Sirachainan; Andrew Hill; Kwang Wook Suh; Frank Beier; Sudipto Chatterjee; Robert Lim. E Clin Colorectal Cancer 2016.
FOLFIRI plus either sunitinib or placebo in metastatic colorectal cancer: a phase III trial. A Carrato, A Swieboda-Sadlej, M Staszewska-Skurczynska, R Lim, L Roman, Y Shparyk, I Bondarenko, D Jonker, Y Sun, JA De la Cruz, JA Williams, B Korytowsky, X Lin, JM Tursi, MJ Lechuga, E Van Cutsem. Journal of Clinical Oncology 2013; 31 (10) 1341 – 1347.
Cetuximab plus irinotecan in patients from the Asia-Pacific region with pretreated metastatic colorectal cancer progressing on irinotecan: The ELSIE study. Robert Lim, Yan Sun, Seock-Ah Im, Ruey-Kuen Hsieh, Tsz Kok Yau, Anthony Bonaventura, Arkom Cheirsilpa, Regina Esser, Matthias Mueser, Suresh Advani. World Journal of Gastroenterology 2011; 17(14): 1879 – 1888.
FOLFIRI with and without cetuximab in the first-line treatment of metastatic colorectal cancer: efficacy, safety and KRAS Eric Van Cutsem, Istvan Lang, Jerzy Zaluski, Chung-Rong Chang Chien, Anatoly Makhson, Geert D’Haens, Tamás Pintér, Robert Lim, Győrgy Bodoky, Jae Kyung Roh, Gunnar Folprecht, Paul Ruff, Johannes Nippgen, Christopher Stroh, Sabine Tejpar, Michael Schlichting, Philippe Rougier. The New England Journal of Medicine 2009; 360: 1408 -1417.